TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
1.110
-0.010 (-0.89%)
At close: Aug 1, 2025, 4:00 PM
1.110
0.00 (0.00%)
After-hours: Aug 1, 2025, 4:00 PM EDT

Augmedix Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Augmedix.

Price Target: $0.00 (0.00%)
Analyst Consensus: n/a
TargetLowAverageMedianHigh
Pricen/an/an/an/a
Changen/an/an/an/a

Analyst Ratings

There are currently no analyst ratings available for Augmedix.

Recommendation Trends

RatingMar '23Apr '23May '23Jun '23Jul '23Aug '23
Strong Buy000000
Buy000000
Hold222220
Sell000000
Strong Sell000000
Total222220

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Reiterates
$5
HoldReiterates$5+350.45%Aug 17, 2023
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Initiates
$5
HoldInitiates$5+350.45%Jan 11, 2023
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Reiterates
$1
HoldReiterates$1-9.91%Jul 13, 2022
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Downgrades
$10
HoldDowngrades$10+800.90%Jun 7, 2022
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Downgrades
$250$50
HoldDowngrades$250$50+4,404.50%May 6, 2022
More Analyst Ratings

Financial Forecast

Revenue This Year
9.28M
from 1.76M
Increased by 427.09%
Revenue Next Year
n/a
from 9.28M
EPS This Year
0.36
from -0.19
EPS Next Year
n/a
from 0.36
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue
64.87M2.57M69.96M1.30M1.76M9.28M
Revenue Growth
30.67%-96.03%2,619.12%-98.14%35.25%427.09%
EPS
-33.50-21.6611.95-0.99-0.190.36
EPS Growth
------
Forward PE
-----3.11
No. Analysts
-----3
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue2025
High9.6M
Avg9.3M
Low8.9M

Revenue Growth

Revenue Growth2025
High
442.6%
Avg
427.1%
Low
406.4%

EPS Forecast

EPS2025
High0.37
Avg0.36
Low0.34

EPS Growth

EPS Growth2025
High-
Avg-
Low-
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.